Lisata Therapeutics, INC 10-Q quarterly reports

Lisata Therapeutics reports Q1 2026 results, detailing progress on its proposed acquisition by Kuva Labs, Inc., and a net loss of $4.49 million.

Lisata Therapeutics reported a reduced net loss in the third quarter of 2025, driven by lower operating expenses, while its lead cancer drug certepetide showed promising clinical results in pancreatic cancer trials and secured new licensing deals.

Lisata Therapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses and initial revenue, while advancing its lead oncology drug, certepetide, and securing a new patent.

Lisata Therapeutics reports a net loss of $4.724 million for Q1 2025, with a focus on advancing its clinical-stage drug, certepetide, for solid tumor treatment.

Lisata Therapeutics reported a net loss of $4.9 million for the third quarter of 2024, with a focus on advancing its clinical-stage cancer therapies.

Lisata Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, while highlighting ongoing clinical trials for its lead drug candidate, certepetide.

Lisata Therapeutics reported a net loss of $5.4 million for the first quarter of 2024, while continuing to advance its clinical programs.